Physician profile
Bryan Thames Green
NPI 1861485963
$12,413.20
in general payments reported to CMS, 2019-2025
40 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,293 · 2020: $1,065 · 2021: $1,284 · 2022: $1,512 · 2023: $1,769 · 2024: $1,530 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,211 · Education: $48.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,211.28 |
| Education | $48.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,021.70 | 2019-2025 | |
| Medtronic USA, INC. | $2,098.34 | 2019 | |
| Janssen Biotech, INC. | $920.97 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $852.65 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $828.66 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $482.09 | 2019-2025 | |
| Gilead Sciences, INC. | $468.16 | 2019-2025 | |
| Genzyme Corporation | $468.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $445.20 | 2019-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $328.13 | 2020-2025 | Linzess |
| Aimmune Therapeutics, INC. | $227.84 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $224.76 | 2021-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $214.28 | 2021-2023 | |
| Ardelyx, INC. | $194.18 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $180.62 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $164.48 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $159.71 | 2020-2025 | Rebyota, Cimzia |
| Daiichi Sankyo INC. | $107.78 | 2019-2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $98.88 | 2019-2025 | Tremfya |
| Medtronic, INC. | $96.33 | 2024-2025 | Gi Genius, Pillcam |
| Amgen INC. | $89.17 | 2021-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $87.39 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $75.18 | 2024-2025 | Iqirvo |
| Romark Laboratories, Lc | $73.55 | 2019 | |
| Allergan, INC. | $68.70 | 2019 | |
| Celltrion USA INC. | $66.80 | 2024-2025 | Zymfentra, Vegzelma |
| Intercept Pharmaceuticals, INC. | $62.10 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $40.51 | 2024-2025 | Voquezna |
| Organon LLC | $38.65 | 2021-2025 | |
| Ucb, INC. | $38.11 | 2019 | |
| Braintree Laboratories, INC. | $36.13 | 2019-2021 | |
| Mauna Kea Technologies, INC. | $29.22 | 2024 | |
| Shionogi INC | $26.25 | 2019 | |
| Vivus LLC | $25.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.58 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $15.56 | 2019 | |
| Pharmacosmos Therapeutics INC. | $14.61 | 2021 | |
| Laborie Medical Technologies Corp. | $14.25 | 2025 | |
| Alfasigma USA, INC. | $11.96 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.